Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18F-FT-FAPI
- Development stage
- Unknown
- Lead developer
- Xijing Hospital
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
18F-FT-FAPI is a positron emission tomography (PET) radiotracer designed to target fibroblast activation protein alpha (FAP), a protein highly expressed on cancer-associated fibroblasts (CAFs) within the tumor microenvironment and in various fibrotic conditions. Developed by researchers at the First Affiliated Hospital of the People's Liberation Army Air Force Military Medical University (Xijing Hospital), this tracer utilizes the fluorine-18 isotope, which offers advantages such as a longer half-life (110 minutes) compared to gallium-68, enabling centralized production and high-resolution imaging. The ligand, FT-FAPI, is a small molecule inhibitor derivative that binds with high affinity to FAP. It is currently being evaluated in clinical studies to assess its safety, biodistribution, and diagnostic utility in healthy volunteers and potentially in patients with various malignancies or fibrotic diseases.
- Other names
- [18F]FT-FAPI
02
Targets
FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on 18F-FT-FAPI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 18F-FT-FAPI.